Interferon treatment of two patients with quadruple infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis G virus (HGV), and TT virus (TTV).
We administered interferon (IFN) to two patients who had quadruple infection with hepatitis C virus (HCV), human immunodeficiency virus (HIV), hepatitis G virus (HGV), and TT virus (TTV), a recently isolated novel DNA virus. Nine mega-units of natural alpha-IFN were administered daily during the first two weeks and thrice weekly during the following 22 weeks (total dose, 720 mega-units). In both cases, serum alanine aminotransferase (ALT) levels decreased during IFN administration but increased thereafter. The concentrations of HCV, HIV, HGV, and TTV declined with the administration of IFN. However, the concentrations of these 4 viruses increased after the cessation of IFN with the except of TTV in patient 2 which disappeared during treatment and did not subsequently reappear. IFN reduced the concentrations of 4 viruses, in an apparently independent manner.
Toyoda
H
H
Second Department of Internal Medicine, Nagoya University School of Medicine, Japan.
Fukuda
Y
Y
Yokozaki
S
S
Nakano
I
I
Hayakawa
T
T
Takamatsu
J
J
D000328:Adult; D000410:Alanine Transaminase / Q000097:blood; D000998:Antiviral Agents / Q000627:therapeutic use*; D018791:CD4 Lymphocyte Count; D004266:DNA Virus Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D004267:DNA Viruses / Q000302:isolation & purification / Q000502:physiology; D004279:DNA, Viral / Q000097:blood; D018067:Flaviviridae / Q000302:isolation & purification / Q000502:physiology; D006678:HIV / Q000302:isolation & purification / Q000502:physiology; D015658:HIV Infections / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D002836:Hemophilia B / Q000150:complications; D016174:Hepacivirus / Q000302:isolation & purification / Q000502:physiology; D006526:Hepatitis C / Q000097:blood / Q000188:drug therapy* / Q000821:virology; D006525:Hepatitis, Viral, Human / Q000097:blood / Q000188:drug therapy / Q000821:virology; D006801:Humans; D016898:Interferon-alpha / Q000627:therapeutic use*; D008297:Male; D012367:RNA, Viral / Q000097:blood; D014766:Viremia / Q000188:drug therapy / Q000821:virology
D000998:Antiviral Agents; D004279:DNA, Viral; D016898:Interferon-alpha; D012367:RNA, Viral; D000410:Alanine Transaminase